MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Anti-Breast Cancer Compound Library

MCE 站：Anti-Breast Cancer Compound Library

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, ａnd also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors ａnd human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), ａnd triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, ａnd may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway ａnd Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 1188 compounds with identified ａnd potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Description & Advantages:

•   A unique collection of 1188 compounds with identified ａnd potential anti-breast cancer activity for high throughput screening (HTS) ａnd high content screening (HCS).

•   Targets include kinases, cell cycle key components, tumorigenesis related signaling pathways, popular targets in breast cancer, ａnd more.

•   A useful tool for the discovery of anti-breast cancer drugs.

•   Bioactivity ａnd safety confirmed by preclinical research ａnd clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, ａnd cell permeable.

•   Detailed compound information with structure, IC₅₀, ａnd brief introduction.

•   Validated NMR ａnd HPLC to ensure high purity ａnd quality.

•   All compounds are in stock ａnd continuously updated.

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。